0000886163-18-000042.txt : 20180306
0000886163-18-000042.hdr.sgml : 20180306
20180306183649
ACCESSION NUMBER: 0000886163-18-000042
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180305
FILED AS OF DATE: 20180306
DATE AS OF CHANGE: 20180306
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: LAMATTINA JOHN L
CENTRAL INDEX KEY: 0001216074
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 18671346
MAIL ADDRESS:
STREET 1: 81 WYMAN ST
STREET 2: POST OFFICE BOX 9046
CITY: WALTHAM
STATE: MA
ZIP: 02454
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2018-03-05
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001216074
LAMATTINA JOHN L
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2018-03-05
4
M
0
3335
10.12
A
24291
D
Common Stock
2018-03-05
4
S
0
3335
160.9007
D
20956
D
Non-Qualified Stock Option (right to buy)
10.12
2018-03-05
2018-03-05
4
M
0
3335
0.0
D
2021-06-01
Common Stock
3335
0
D
The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 05, 2017, in accordance with Rule 10b5-1.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.03 to $161.94, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 01, 2011, and fully vested on the first anniversary of the grant date.
By: Charles S. Berkman For: John L. LaMattina
2018-03-06